tirzepatide vs semaglutide weight loss study Versus on in Type 2 Diabetes Patients: A Systematic Review and Meta‐Analysis of Direct Comparative Studies Sherika Newman | Doctor g-series Bundles:6 Bottles

tirzepatide vs semaglutide weight loss study Versus on in Type 2 Diabetes Patients: A Systematic Review and Meta‐Analysis of Direct Comparative Studies Sherika Newman | Doctor g-series Bundles:6 Bottles

Sherika Newman | Doctor In The Family | GLP-1 medications aren't magic. They're science. And understanding how they work changes everything about how you use them. Here's what... | Instagram

Specific receptor mechanisms include: GLP-1 receptor activation : Delays gastric emptying, increases glucose-dependent insulin secretion, suppresses glucagon GIP receptor activation : Enhances postprandial insulin secretion, improves lipid metabolism, enhances GLP-1 action Glucagon receptor activation : Enhances satiety signaling, increases lipolysis, promotes thermogenesis The synergistic combination of these three receptor agonisms distinguishes retatrutide from single-pathway ( GLP-1 only ) or dual-pathway ( GLP-1/GIP ) agonists, making it a unique compound in metabolic research

g-series

Bundles:6 Bottles

Based on the observation that a large proportion of lean tissues lost during weight loss seems to be from our adipose tissue, and the proportion of total lean mass increased after weight loss in STEP 1 and SUSTAIN 8 trials, it’s unlikely that using semaglutide to support weight loss leads to clinically meaningful reductions in muscle and other lean tissues